Published in J Exp Med on April 01, 1972
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52
Evidence for the clonal abortion theory of B-lymphocyte tolerance. J Exp Med (1975) 2.61
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
In vitro tolerance induction of neonatal murine B cells. J Exp Med (1976) 2.33
The use of bacterial lipopolysaccharides to show that two signals are required for the induction of antibody synthesis. J Exp Med (1973) 2.30
Termination of tolerance to human gamma globulin in mice by antigen and bacterial lipopolysaccharide (endotoxin). J Exp Med (1973) 2.15
Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway. J Immunol (2014) 2.11
Cellular requirements for the primary in vitro antibody response to DNP-ficoll. J Exp Med (1974) 2.10
Mechanism of thymus-independent immunocyte triggering. Mitogenic activation of B cells results in specific immune responses. J Exp Med (1974) 2.04
Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96
Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration. J Exp Med (1972) 1.77
Effector cell blockade. A new mechanism of immune hyporeactivity induced by multivalent antigens. J Exp Med (1974) 1.75
Influence of molecular structure on the tolerogenicity of bacterial dextrans. I. The alpha1--6-linked epitope of dextran B512. Immunology (1975) 1.56
Studies on the differentiation of B lymphocytes in the mouse. Immunology (1973) 1.46
Induction of B cell tolerance in vitro to 2,4-dinitrophenyl coupled to a copolymer of D-glutamic acid and D-lysine (DNP-D-GL). J Exp Med (1973) 1.45
Activation of antibody Fc function by antigen-induced conformational changes. Proc Natl Acad Sci U S A (1975) 1.27
Stimulation of T-independent antibody responses by hapten-lipopolysaccharides without repeating polymeric structure. Infect Immun (1979) 1.24
Production of a runting syndrome and selective A deficiency in mice by the administration of anti-heavy chain antisera. J Exp Med (1973) 1.22
Antigen-induced aggregation and modulation of receptors on hapten-specific B lymphocytes. J Exp Med (1976) 1.12
Evidence for a long-range conformational change induced by antigen binding to IgM antibody. Proc Natl Acad Sci U S A (1977) 1.07
Induction of immunity and tolerance in vitro by hapten protein conjugates. 3. Hapten inhibition studies of antigen binding to B cells in immunity and tolerance. J Exp Med (1972) 1.05
Role of antigenic structure in cell to cell cooperation. Proc Natl Acad Sci U S A (1976) 1.04
T and B cell in hapten-specific carrier-determined tolerance. J Exp Med (1975) 1.03
Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med (1995) 1.02
Differential tolerance of thymus-independent and thymus-dependent antibody responses. Immunology (1978) 0.96
The inter-relationship of antigenic structure, thymus-independence and adjuvanticity. IV. A general model for B-cell induction. Immunology (1975) 0.92
The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? Bull World Health Organ (1990) 0.90
Defective B cell tolerance in adult (NZB X MZW)F1 mice. J Exp Med (1980) 0.89
Specific cellular stimulation in the primary immune response: experimental test of a quantized model. Proc Natl Acad Sci U S A (1982) 0.88
Inhibition of antibody formation during continual stimulation with a strong immunogen. Immunology (1974) 0.85
The in vitro induction of immunological tolerance in the B lymphocyte by oligovalent thymus-dependent antigens. J Exp Med (1975) 0.85
Immunity to murine sarcoma virus induced tumours. 3. Analysis of the cell populations involved in protection from lethal tumour progression of sublethally irradiated, MSV inoculated, mice. Br J Cancer (1974) 0.79
Partial characterization of a T cell-derived factor that suppresses the initiation of the humoral immune response in vitro. Immunology (1977) 0.79
Studies on the immune response in chickens. III. Effect of substitution of carrier on elicitation of anti-hapten antibody responses and generation of hapten-specific memory. Immunology (1979) 0.75
Partial characterization of an immunoenhancing factor from allogeneic human lymphocyte cell lines. Immunology (1976) 0.75
Immunization of dissociated spleen cell cultures from normal mice. J Exp Med (1967) 30.93
Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology (1968) 24.83
ANTIGENS IN IMMUNITY. I. PREPARATION AND PROPERTIES OF FLAGELLAR ANTIGENS FROM SALMONELLA ADELAIDE. Aust J Exp Biol Med Sci (1964) 10.00
Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. J Exp Med (1968) 9.67
Determination of cell viability. Proc Soc Exp Biol Med (1958) 5.86
Studies on artifical antigens. I. Antigenicity of DNP-polylysine and DNP copolymer of lysine and glutamic acid in guinea pigs. J Exp Med (1963) 5.72
The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03
An in vitro primary immune response to 2,4,6-trinitrophenyl substituted erythrocytes: response against carrier and hapten. J Immunol (1970) 3.63
Immunogenicity of trinitrophenyl-hemocyanin: production of primary and secondary anti-hapten precipitins. J Immunol (1966) 3.56
Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med (1970) 2.54
Immunological tolerance in vitro: kinetic studies at the cellular level. J Exp Med (1969) 2.37
Induction of antibody formation and tolerance in vitro to a purified protein antigen. Lancet (1967) 2.32
Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17
Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93
The immune response of normal, irradiated and thymectomized mice to fowl immunoglobulin G as detected by a hemolytic plaque technique. Int Arch Allergy Appl Immunol (1971) 1.85
Hapten competition and the nature of cell-cooperation in the antibody response. Proc R Soc Lond B Biol Sci (1971) 1.85
Induction of immunity and tolerance in vitro in the absence of phagocytic cells. Nature (1970) 1.64
Regulation of antibody synthesis against Escherichia coli endotoxin. IV. Induction of paralysis in vitro by treating normal lymphoid cells with antigen. J Exp Med (1969) 1.50
Antibody-mediated suppression of the immune response in vitro. 3. Low zone tolerance in vitro. Immunology (1971) 1.47
Induction of immunological tolerance by a hapten (DNP) bound to a non-immunogenic protein carrier. Nat New Biol (1971) 1.34
In vitro induction of a primary response to the dinitrophenyl determinant. J Exp Med (1970) 1.10
Kinetics of in vitro initiated secondary anti-hapten response: induction of plaque-forming cells by soluble and particulate antigen. Immunochemistry (1970) 1.02
Induction of low-zone tolerance in vitro. Transplant Proc (1971) 0.84
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet (1983) 5.64
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03
HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature (1987) 2.96
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med (1980) 2.88
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol (1996) 2.85
Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology (2005) 2.79
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry (2006) 2.65
T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. Transplant Rev (1972) 2.44
Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science (1985) 2.27
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells. J Exp Med (1977) 2.22
Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Tolerance of T-cell clones is associated with membrane antigen changes. Nature (1983) 2.10
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol (1976) 2.05
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev (1972) 2.02
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A (1998) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol (1998) 1.96
Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96
Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Role of macrophages in in vitro induction of T-helper cells. Nature (1975) 1.84
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
B Cell heterogeneity - difference in the size of B lymphocytes responding to T dependent and T independent antigens. Cell Immunol (1975) 1.78
Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration. J Exp Med (1972) 1.77
Suppressor-cell induction in vitro. IV. Target of antigen-specific suppressor factor and its genetic relationships. J Exp Med (1978) 1.77
Synergy among thymocytes and peripheral lymph node cells in the in vitro generation of lymphocytes cytotoxic to alloantigens. Transplant Proc (1973) 1.76
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Monospecificity of bone marrow-derived lymphocytes. J Exp Med (1973) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol (1988) 1.69
Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. Cell Immunol (1972) 1.67
Suppressor cell induction in vitro. I. Kinetics of induction of antigen-specific suppressor cells. Eur J Immunol (1976) 1.65
Migrainous vertigo: prevalence and impact on quality of life. Neurology (2006) 1.64
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev (1995) 1.63
The role of macrophages in the generation of T-helper cells. I. The requirement for macrophages in helper cell induction and characteristics of the macrophage-T cell interaction. Cell Immunol (1975) 1.62
Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol (1994) 1.61
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
Role of macrophages in the generation of T helper cells. IV. Nature of genetically related factor derived from macrophages incubated with soluble antigens. Eur J Immunol (1976) 1.57
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol (1997) 1.54
Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A (1999) 1.54
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 1.53
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol (1997) 1.52
Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest (2000) 1.50
Specific collaboration between T and B lymphocytes across a cell impermeable membrane in vitro. Nat New Biol (1972) 1.49
Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology (1988) 1.48
Induction of immunity and tolerance in vitro by hapten protein conjugates. II. Carrier independence of the response to dinitrophenylated polymerized flagellin. Eur J Immunol (1972) 1.47
Antibody-mediated suppression of the immune response in vitro. 3. Low zone tolerance in vitro. Immunology (1971) 1.47
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol (1997) 1.46
Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol (1992) 1.44
Nonphagocytic dendritic cells are effective accessory cells for anti-mycobacterial responses in vitro. J Immunol (1985) 1.42
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A (1994) 1.42
The requirement for macrophages in the secondary immune response to antigens of small and large size in vitro. Immunology (1971) 1.40
Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A (1990) 1.40
Conditions for inducing T helper cells in vitro. Scand J Immunol (1975) 1.39
Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol (1999) 1.35
Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci U S A (1991) 1.33
Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) 1.33
T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun (1988) 1.32
Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol (1996) 1.31
Long-term human T-helper lines producing specific helper factor reactive to influenza virus. Nature (1981) 1.30
The cellular pathway of antigen presentation: biochemical and functional analysis of antigen processing in dendritic cells and macrophages. Immunology (1986) 1.28
Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol (2001) 1.27